All In MedTech

Device Trial Radar · NCT05344521

A Phase I, Single-blind, Randomized Study of the Safety and Efficacy of Cellularized Integra® Using Autologous Burn-derived Stem Cells

Last checked: Nov 20, 2026Latest source record: Dec 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

29

Planned (sponsor's estimate)

Start

Feb 2024

Primary completion

Feb 2026

Study completion Feb 2027

Sponsor

Lead sponsor
Hamilton Health Sciences CorporationAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
AFP Innovation Fund; Ontario Institute for Regenerative Medicine; Stem Cell Network
First posted
Apr 25, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Burn injuries are one of the most severe skin injuries and lead to a complex wound healing response. When the skin is wounded, stem cells in the skin must respond fast to help repair the injured tissue. The damaged skin of burn patients contains cells that are still alive and have typical stem cell characteristics. Because stem cells are so important for wound healing, the investigators have combined them with an existing skin substitute, Integra®, to examine the potential wound healing benefits of these stem cells. This is an investigational treatment and a first in-human trial. The purpose of this study is to test the safety of using a patient's own stem cells combined with Integra®, which the investigators call Integra®-Stem Cells (Integra®-SC). The investigators hypothesize that Integra®-SC will result in improved wound healing, better scar quality, and decreased scar formation at one-year post-injury.

Conditions

  • Burns

Interventions

  • Integra®Device

    A commercially available dermal bovine matrix that is widely used for wound and burn care, Integra® Dermal Regeneration Template licensed device (Medical Device Active License Listing No. 229).

  • Integra®-SCDevice

    A combination of Integra® incorporated with 5,000-20,000 cells/cm2 of autologous burned derived stem cells.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety - Number of participants with surgical site infectionsTime frame: Acute hospitalization (1-4 months post admission depending on severity of injury)
  2. Safety - Number of participants with non-healing woundsTime frame: Acute hospitalization (1-4 months post admission depending on severity of injury)
  3. Safety - Number of patients with poor scarring requiring additional (unplanned) operationTime frame: Discharge to to 1 year post-discharge

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hamilton General Hospital

    Hamilton, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.